UW Cost-Effectiveness Modeling Team, Ryan Hansen and Greg Guzauskas, were recently presenters at the Institute for Clinical and Economic Review’s (ICER) New England CEPAC Meeting on Type 2 Diabetes at Brown University in Providence, Rhode Island.
The UW Team created a cost-effectiveness microsimulation model to evaluate the value of oral semaglutide added to ongoing background diabetes treatment compared to four alternative treatment strategies. Drs. Hansen and Guzauskas were praised for a very effective presentation of a complex disease model by both the ICER Policy Roundtable Participants and the CEPAC Members.
The New England Comparative Effectiveness Public Advisory Council (New England CEPAC), a core program of the Institute for Clinical and Economic Review (ICER), is a nationally-recognized community forum. The New England CEPAC convenes three times each year at public meetings to review objective evidence reports and develop recommendations for how stakeholders can apply evidence to improve the quality and value of health care.
New England CEPAC directly engages clinicians, patients, and payers during public meetings to discuss implications of the evidence for clinical decision-making and coverage policies. Application of evidence takes shape through new medical policies, benefit designs, and patient and clinician tools to improve clinical care and patient outcomes.
Learn more here: https://icer-review.org/programs/new-england-cepac/
Dr. Ryan Hansen is an Assistant Professor in the CHOICE Institute and Dr. Greg Guzauskas is a Senior Research Scientist in the CHOICE Institute.